Results 191 to 200 of about 136,889 (307)

Prediction of HIV-1 protease resistance using genotypic, phenotypic, and molecular information with artificial neural networks. [PDF]

PeerJ, 2023
Tunc H, Dogan B, Darendeli Kiraz BN, Sari M, Durdagi S, Kotil S.   +5 more
europepmc   +1 more source

HIV‐1 establishes immediate latency in T cells expressing the viral Nef protein

FEBS Open Bio, Volume 16, Issue 6, Page 1132-1141, June 2026.
Nef is a viral protein often omitted from HIV‐1 reporter viruses. Consequently, its role in viral latency is unclear. We developed three novel dual reporter HIV‐1 derivatives that express Nef and allow for detection of latent and productive infection. Using these reporters, we show that Nef does not affect the establishment of immediate viral latency ...
Cindy Lam, Ivan Sadowski
wiley   +1 more source

A Highly Sensitive BRET-Based Reporter for Live-Cell Detection of HIV-1 Protease Activity and Inhibitor Screening. [PDF]

Viruses
Centazzo M, Djossou AV, Pavan S, Alvisi G.   +3 more
europepmc   +1 more source

Effectively predicting HIV-1 protease cleavage sites by using an ensemble learning approach. [PDF]

BMC Bioinformatics, 2022
Hu L, Li Z, Tang Z, Zhao C, Zhou X, Hu P.   +5 more
europepmc   +1 more source

The impact of a UK HIV-1 resistance database for the management and improvement of the clinical care of people living with HIV-1

Background: The introduction of highly active antiretroviral therapies (HAART) in 1996 to treat patients living with the human immunodeficiency virus type 1 (HIV-1), led to dramatic improvements in their mortality and morbidity.
MacRae, Eilidh
core  

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Factors Influencing the Binding of HIV-1 Protease Inhibitors: Insights from Machine Learning Models. [PDF]

ChemMedChem
Shalit Y, Tuvi-Arad I.
europepmc   +1 more source

Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. [PDF]

Chem Commun (Camb), 2022
Ghosh AK, Weber IT, Mitsuya H.
europepmc   +1 more source

Enhanced Human Antigen‐Specific B Cell Responses Using In Vitro 3D Tonsil Cultures Containing Stromal Cells

Advanced Healthcare Materials, Volume 15, Issue 22, 12 June 2026.
We developed a fully human 3D tonsil cell culture system incorporating supportive stromal cells that better sustains and activates immune cells than conventional methods. The model generates stronger, more targeted antibody responses to viral antigens and vaccines, providing a physiologically relevant and entirely human platform for studying immune ...
Maaike V. J. Braham, Marlon de Gast, Liubov Babii, Sabine Kruijer, Theo M. Bestebroer, Mathilde Richard, Mathieu Claireaux, S. Marieke van Ham, Jelle de Wit, Cécile A. C. M. van Els, Anja ten Brinke, Marit J. van Gils   +11 more
wiley   +1 more source

Ligand Versatility and Resistance Mechanism of Monotherapy-Grade HIV-1 Protease Inhibitor GRL-142 Binding the Multidrug Resistant Variant p51: Insights from 1 μs MD Simulations. [PDF]

J Chem Inf Model
Arias A, Cappelli C, Restrepo A, Alí-Torres J, Gómez S.   +4 more
europepmc   +1 more source